Cambridge, Mass., and Madison, Wis. – BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM Cellular Dynamics, Inc.
Innovation and growth remain a priority to support customers and COVID-19 initiatives
SANTA ANA, California - FUJIFILM Irvine Scientific, Inc. is celebrating its 50th year of providing innovative cell culture media products and services. Since its formation, the Company has established a reputation as an innovator and leader in providing cell culture solutions for the Life Science and Medical markets.
Fujifilm to invest $2 Billion and create 725 jobs with its new state-of-the-art large-scale cell culture manufacturing facility in Holly Springs, North Carolina
TOKYO ― FUJIFILM Corporation (President: Kenji Sukeno) has announced the selection of Holly Springs, North Carolina as the location for its new large-scale cell culture production site in the United States.
MADISON, Wis. and SEATTLE - FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC) technologies, and Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, announced today that Sana has been granted a non-exclusive right to use FUJIFILM Cellular Dynamics’ iPSC platform for the development of commercial cell therapies.
Signing a business partnership agreement on the contract development and manufacturing of regenerative medicine products
TOKYO – FUJIFILM Corporation (President: Kenji Sukeno) announces that it signed an agreement today to invest 100 million yen into a biotech venture, Cuorips Inc. through underwriting its third-party allocation of shares. Cuorips is a biotech venture for developing and commercializing iPSC-based treatment for heart failure.
End-to-End Single-Site Solution from Drug Substances to Fill-Finish & Packaging
TOKYO ― FUJIFILM Corporation (President: Kenji Sukeno) is making an investment of more than 200 Billion yen (2 Billion USD) to establish a new large-scale cell culture production site in the United States to accelerate the growth of its biopharmaceutical contract development and manufacturing business (CDMO).
Billingham, United Kingdom – FUJIFILM Diosynth Biotechnologies, is pleased to share that Steve Bagshaw, non-executive chairman of FUJIFILM Diosynth Biotechnologies, has been awarded Commander of the Most Excellent Order of the British Empire (CBE) for Services to the U.K. Manufacturing and Biotechnology Sector in the New Years Honors List 2021.
Establishing a presence in Massachusetts within the academia and pharma communities to perform cutting-edge research and innovation in the field of advanced therapies.
CAMBRIDGE, Mass - FUJIFILM Holdings America Corporation (Fujifilm), announced that five new recipients have been awarded the Fujifilm Fellowship at Harvard Medical School (HMS). Since its launch in 2019, the program has provided 11 fellowships for Ph.D. students who are enrolled at HMS, and focused on translational medicine, the process of applying basic research in the laboratory for new therapeutic development.
TOKYO — FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada) has announced that the company has partnered with Chinese pharmaceutical company Carelink Pharmaceutical Co., Ltd. (hereinafter “Carelink”) in deploying anti-influenza drug Avigan® Tablets (generic name: favipiravir,“Avigan”) in China. Going forward, through a future application and approval of Avigan for imported drug registration, to be submitted by Carelink, FUJIFILM Toyama Chemical aims to introduce Avigan to the Chinese market.
TOKYO — FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada; hereinafter “FUJIFILM Toyama Chemical”) has announced that the company filed an Application for Partial Changes to manufacturing and marketing approval matters of its anti-influenza drug Avigan® Tablet (generic name: favipiravir,”Avigan”) to the Ministry of Health, Labour and Welfare in Japan. The filing seeks to add an indication and other items relating to novel coronavirus infections (hereinafter “COVID-19”).
HILLERØD, Denmark - FUJIFILM Diosynth Biotechnologies, a world leading Contract Development and Manufacturing Organization (CDMO) for biologics, viral vaccines and viral vectors, today announced that it will manufacture Eli Lilly and Company’s COVID-19 therapeutic antibody at its GMP1 facility in Hillerød, Denmark, deploying capacity reserved for the COVID-19 Therapeutics Accelerator.
MILAN (Italy) and MADISON (Wis., USA) – Axxam S.p.A., a leading provider of integrated drug discovery services across life sciences industries, and FUJIFILM Cellular Dynamics, Inc., a leading developer and manufacturer of human induced pluripotent stem cell (hiPSC) models and therapies, announce a strategic alliance to improve the drug discovery process.
TOKYO - FUJIFILM Corporation (President: Kenji Sukeno) is expanding its gene therapy offering, with the addition of viral vector process development and GMP1 manufacturing services at FUJIFILM Diosynth Biotechnologies’ in the North East of the United Kingdom (UK).
-Process development and manufacture of formulations using lipid nanoparticles Drug Delivery System technology-
TOKYO—FUJIFILM Corporation (President: Kenji Sukeno) announces the conclusion of a manufacturing contract agreement with biotechnology company, VLP Therapeutics Japan LLC (Representative Executor: Wataru Akahata, hereinafter “VLP Therapeutics”) regarding COVID-19 vaccine formulation developed by VLP Therapeutics.
LONDON and TOKYO ― Centus Biotherapeutics Ltd., a joint venture between Fujifilm Kyowa Kirin Biologics Co., Ltd. and AstraZeneca, today announced that the European Commission (EC) has granted the marketing authorization for Equidacent® (Product Code: FKB238), the company’s biosimilar to Avastin® (bevacizumab).
TOKYO — FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada; hereinafter “FUJIFILM Toyama Chemical”) has announced today that primary endpoint has been met in phase III clinical trial of “Avigan Tablet” (generic name: favipiravir, “Avigan”) conducted in Japan for patients with novel coronavirus infections (hereinafter “COVID-19”). The efficacy primary endpoint is time to negative conversion of detectable SARS-CoV 2 viral RNA in the RT-PCR assays, and to alleviation of symptoms (body temperature, oxygen saturation and chest images).